Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.16
ZTS's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 0.16 )
ZTS' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.16

Equity to Asset 0.19
ZTS's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 0.19 )
ZTS' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.69
Current: 0.19

0.12
0.69
Interest Coverage 7.03
ZTS's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 7.03 )
ZTS' s 10-Year Interest Coverage Range
Min: 2.3   Max: 13.28
Current: 7.03

2.3
13.28
F-Score: 7
Z-Score: 3.73
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.65
ZTS's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 18.65 )
ZTS' s 10-Year Operating margin (%) Range
Min: -4.53   Max: 17.41
Current: 18.65

-4.53
17.41
Net-margin (%) 11.43
ZTS's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 11.43 )
ZTS' s 10-Year Net-margin (%) Range
Min: -3.62   Max: 11.05
Current: 11.43

-3.62
11.05
ROE (%) 53.56
ZTS's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 53.56 )
ZTS' s 10-Year ROE (%) Range
Min: 11.26   Max: 20.3
Current: 53.56

11.26
20.3
ROA (%) 8.23
ZTS's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 8.23 )
ZTS' s 10-Year ROA (%) Range
Min: 7.28   Max: 8.58
Current: 8.23

7.28
8.58
ROC (Joel Greenblatt) (%) 31.04
ZTS's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 31.04 )
ZTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.88   Max: 36.32
Current: 31.04

25.88
36.32
» ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ZTS Guru Trades in Q3 2013

Lee Ainslie 359,948 sh (New)
Jean-Marie Eveillard 5,842,948 sh (+1447.21%)
Ruane Cunniff 173,973 sh (+767.96%)
Mario Gabelli 244,760 sh (+350.26%)
John Keeley 81,519 sh (+95.24%)
RS Investment Management 2,266,289 sh (+24.05%)
Robert Olstein 160,000 sh (+11.89%)
Chuck Royce 5,000 sh (unchged)
Steven Cohen 108,700 sh (unchged)
Steven Cohen 600,000 sh (unchged)
Vanguard Health Care Fund 8,412,017 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 6,475,368 sh (-13.77%)
Pioneer Investments 1,925,278 sh (-27.86%)
George Soros 1,619,011 sh (-32.68%)
Louis Moore Bacon 15,950 sh (-68.1%)
» More
Q4 2013

ZTS Guru Trades in Q4 2013

Paul Tudor Jones 6,200 sh (New)
Jim Simons 779,000 sh (New)
Lee Ainslie 7,635,025 sh (+2021.15%)
George Soros 2,495,329 sh (+54.13%)
Mario Gabelli 282,960 sh (+15.61%)
Jean-Marie Eveillard 6,647,674 sh (+13.77%)
John Keeley 81,582 sh (+0.08%)
George Soros 186,000 sh (unchged)
Vanguard Health Care Fund 8,412,017 sh (unchged)
Robert Olstein 160,000 sh (unchged)
Ruane Cunniff 173,973 sh (unchged)
Louis Moore Bacon Sold Out
Chuck Royce Sold Out
Pioneer Investments 1,924,824 sh (-0.02%)
RS Investment Management 2,234,184 sh (-1.42%)
Steven Cohen 4,749,899 sh (-26.65%)
» More
Q1 2014

ZTS Guru Trades in Q1 2014

Joel Greenblatt 42,374 sh (New)
Paul Tudor Jones 15,774 sh (+154.42%)
George Soros 4,205,043 sh (+68.52%)
Vanguard Health Care Fund 10,421,717 sh (+23.89%)
RS Investment Management 2,687,539 sh (+20.29%)
Robert Olstein 178,000 sh (+11.25%)
Lee Ainslie Sold Out
Ruane Cunniff 173,553 sh (-0.24%)
Pioneer Investments 1,913,056 sh (-0.61%)
John Keeley 79,108 sh (-3.03%)
Mario Gabelli 260,552 sh (-7.92%)
Jean-Marie Eveillard 3,763,386 sh (-43.39%)
Jim Simons 163,303 sh (-79.04%)
Steven Cohen 683,462 sh (-85.61%)
» More
Q2 2014

ZTS Guru Trades in Q2 2014

Pioneer Investments 2,254,815 sh (+17.86%)
George Soros 4,386,635 sh (+4.32%)
Vanguard Health Care Fund 10,798,417 sh (+3.61%)
Ruane Cunniff 173,562 sh (+0.01%)
Robert Olstein 178,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
RS Investment Management 2,548,819 sh (-5.16%)
John Keeley 74,504 sh (-5.82%)
Mario Gabelli 242,980 sh (-6.74%)
Joel Greenblatt 33,034 sh (-22.04%)
Jean-Marie Eveillard 2,177,060 sh (-42.15%)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 Reduce -42.15%0.12%$28.4 - $32.89 $ 35.8917%2177060
Joel Greenblatt 2014-06-30 Reduce -22.04%$28.4 - $32.89 $ 35.8917%33034
Lee Ainslie 2014-03-31 Sold Out 3.2%$29.01 - $32.69 $ 35.8917%0
George Soros 2014-03-31 Add 68.52%0.49%$29.01 - $32.69 $ 35.8917%4205043
Jean-Marie Eveillard 2014-03-31 Reduce -43.39%0.26%$29.01 - $32.69 $ 35.8917%3763386
Vanguard Health Care Fund 2014-03-31 Add 23.89%0.16%$29.01 - $32.69 $ 35.8917%10421717
Joel Greenblatt 2014-03-31 New Buy0.02%$29.01 - $32.69 $ 35.8917%42374
Lee Ainslie 2013-12-31 Add 2021.15%3.05%$31.04 - $33.22 $ 35.8913%7635025
George Soros 2013-12-31 Add 54.13%0.24%$31.04 - $33.22 $ 35.8913%2495329
Jean-Marie Eveillard 2013-09-30 Add 1447.21%0.5%$29.15 - $32.72 $ 35.8917%5842948
George Soros 2013-09-30 Reduce -32.68%0.26%$29.15 - $32.72 $ 35.8917%1619011
Lee Ainslie 2013-09-30 New Buy0.15%$29.15 - $32.72 $ 35.8917%359948
Joel Greenblatt 2013-09-30 Sold Out 0.04%$29.15 - $32.72 $ 35.8917%0
Mario Gabelli 2013-09-30 Add 350.26%0.04%$29.15 - $32.72 $ 35.8917%244760
Ruane Cunniff 2013-09-30 Add 767.96%0.03%$29.15 - $32.72 $ 35.8917%173973
John Keeley 2013-09-30 Add 95.24%0.02%$29.15 - $32.72 $ 35.8917%81519
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 34.60
ZTS's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 34.60 )
ZTS' s 10-Year P/E(ttm) Range
Min: 27.31   Max: 42.59
Current: 34.6

27.31
42.59
P/B 14.50
ZTS's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 14.50 )
ZTS' s 10-Year P/B Range
Min: 12.65   Max: 24.37
Current: 14.5

12.65
24.37
P/S 3.90
ZTS's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 3.90 )
ZTS' s 10-Year P/S Range
Min: 3.11   Max: 4.09
Current: 3.9

3.11
4.09
PFCF 53.60
ZTS's PFCF is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 53.60 )
ZTS' s 10-Year PFCF Range
Min: 25.57   Max: 90.29
Current: 53.6

25.57
90.29
EV-to-EBIT 24.71
ZTS's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 24.71 )
ZTS' s 10-Year EV-to-EBIT Range
Min: 20.9   Max: 28.1
Current: 24.71

20.9
28.1
Current Ratio 3.14
ZTS's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 3.14 )
ZTS' s 10-Year Current Ratio Range
Min: 2.29   Max: 3.47
Current: 3.14

2.29
3.47
Quick Ratio 1.88
ZTS's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 1.88 )
ZTS' s 10-Year Quick Ratio Range
Min: 1.35   Max: 1.88
Current: 1.88

1.35
1.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.80
ZTS's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 0.80 )
ZTS' s 10-Year Dividend Yield Range
Min: 0.21   Max: 0.94
Current: 0.8

0.21
0.94
Dividend Payout 0.26
ZTS's Dividend Payout is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 0.26 )
ZTS' s 10-Year Dividend Payout Range
Min: 0.23   Max: 0.31
Current: 0.26

0.23
0.31
Yield on cost (5-Year) 0.80
ZTS's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 0.80 )
ZTS' s 10-Year Yield on cost (5-Year) Range
Min: 0.21   Max: 0.94
Current: 0.8

0.21
0.94

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.11
ZTS's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 1.11 )
ZTS' s 10-Year Price/Median PS Value Range
Min: 0.9   Max: 1.08
Current: 1.11

0.9
1.08
Earnings Yield (Greenblatt) 4.00
ZTS's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ZTS: 4.00 )
ZTS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 4.8
Current: 4

3.6
4.8

Business Description

Industry: »
Compare: » details
Traded in other countries:ZOE.Germany
Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives & other pharmaceutical products.
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Guru Stocks at 52-Week Lows: HMC, NMR, SDRL, ZTS, BBBY Apr 21 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows Apr 10 2014 
Morning Coffee: Guru Stocks Near 52-Week Lows Apr 03 2014 
Guru Stocks at 52-Week Lows: CEO, BCS, HMC, ED, ZTS Apr 01 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows Mar 28 2014 
Steven Cohen's Top Five Holdings Nov 19 2013 
5-Year Lows: Exelon Corp, Grupo Financiero Santander Mexico SAB de CV, Zoetis Inc, Encana Corp Nov 10 2013 
Stocks at 5-Year Lows: BSBT, ZTS, ECA Sep 03 2013 
Consensus Stocks ‘A to Z’ - Second Quarter Action Aug 07 2013 


More From Other Websites
Zoetis Partners With Nestlé To Set Up Dairy Farming Institute In China Oct 16 2014
Zoetis Will Benefit from Industry Trends Oct 07 2014
Today's Market Thorns, Roses and All Time Highs... Oct 06 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 03 2014
Zoetis Declares Fourth Quarter 2014 Dividend Oct 02 2014
ZOETIS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure Oct 02 2014
Zoetis to Host Webcast and Conference Call on Third Quarter 2014 Financial Results Sep 30 2014
Focusing Solely On Animal Health Sets Zoetis Apart Sep 26 2014
Bayer Deal for Zoetis in Sight After Unit Sale: Real M&A Sep 18 2014
Bayer hits record high on move to list plastics business Sep 18 2014
Zoetis Ranked Among Top Ten Companies for Working Mothers Sep 16 2014
ZOETIS INC. Files SEC form 8-K, Change in Directors or Principal Officers Sep 15 2014
The Difference Between Europe and Us Sep 05 2014
[$$] Zoetis Gets Conditional License for Swine Vaccine Sep 03 2014
Zoetis granted conditional license by USDA for PEDv vaccine Sep 03 2014
[video] Cramer's Mad Dash: Zoetis Sep 03 2014
[video] Cramer's stocks to watch: Zoetis' PEDv vaccine Sep 03 2014
Zoetis Granted Conditional License for Porcine Epidemic Diarrhea Vaccine* Sep 03 2014
ZOETIS INC. Financials Aug 20 2014
Zoetis to Participate in Bank of America Merrill Lynch Global Healthcare Conference Aug 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK